Abstract Search

ea0035p907 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Pasireotide LAR demonstrates superior efficacy versus octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: results from a phase III, multicentre, randomized study (PAOLA)

Gadelha Monica , Bronstein Marcello , Brue Thierry , Coculescu Mihail , Fleseriu Maria , Guitelman Mirtha , Pronin Vyacheslav , Raverot Gerald , Shimon Ilan , Lievre Kayo Kodama , Fleck Juergen , Aout Mounir , Pedroncelli Alberto , Colao Annamaria

Background: Some patients with acromegaly do not achieve biochemical control despite receiving maximum-approved doses of currently available somatostatin analogues. This 24-week, randomized study assessed the multireceptor-targeted somatostatin analogue pasireotide LAR vs octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly.Methods: Eligible patients: ≥18 years with mean GH levels ≥2.5 μg/l and IGF1 level...

0 shares

Endocrine Abstracts

Pasireotide LAR demonstrates superior efficacy versus octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: results from a phase III, multicentre, randomized study (PAOLA)

BiosciAbstracts